Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00648414 · ClinicalTrials.gov registry record · Phase 1
Study of the Effect of Clinical Procedures on Drug Delivery of Mylan Fentanyl Transdermal System 25 µg/hr and Duragesic® 25 µg/hr
A Phase 1 study, sponsored by Mylan Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00648414 is a Phase 1 study that was terminated before completion, run by Mylan Pharmaceuticals. The registered enrollment target is 12 participants.
The verdict
NCT00648414, a Phase 1 study, was terminated before completion, sponsored by Mylan Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The objective of this study was to investigate the effect of clinical procedures on the drug delivery of Fentanyl Transdermal Systems, 25 mcg/h manufactured for Mylan Pharmaceuticals Inc. by Mylan Technologies Inc., and Duragesic, 25 mcg/h manufactured for Janssen Pharmaceutica by ALZA Corporation.
Interventions
- DRUG Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1
- DRUG Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2
- DRUG Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3
- DRUG Duragesic 25 mcg/h + Clinical Procedure 1
- DRUG Duragesic 25 mcg/h + Clinical Procedure 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00648414
The ClinicalTrials.gov registry entry for NCT00648414 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan Pharmaceuticals, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1 is the first listed.
NCT00648414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00648414 about?
NCT00648414 is a clinical study titled "Study of the Effect of Clinical Procedures on Drug Delivery of Mylan Fentanyl Transdermal System 25 µg/hr and Duragesic® 25 µg/hr". The objective of this study was to investigate the effect of clinical procedures on the drug delivery of Fentanyl Transdermal Systems, 25 mcg/h manufactured for Mylan Pharmaceuticals Inc. by Mylan Technologies Inc., and Duragesic, 25 mcg/h manufactured for Janssen Pharmaceutica by ALZA Corporation.
What is the current status of trial NCT00648414?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2006-10.
What interventions are being tested in trial NCT00648414?
The interventions under investigation include: Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1 (DRUG), Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2 (DRUG), Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3 (DRUG), Duragesic 25 mcg/h + Clinical Procedure 1 (DRUG), Duragesic 25 mcg/h + Clinical Procedure 2 (DRUG).
Who is sponsoring clinical trial NCT00648414?
This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.